Isabel C Poschke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4496304/publications.pdf

Version: 2024-02-01

15 papers	1,232 citations	623734 14 h-index	996975 15 g-index
15 all docs	15 docs citations	15 times ranked	2655 citing authors

#	Article	IF	Citations
1	Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood, 2022, 139, 142-147.	1.4	63
2	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. OncoImmunology, 2020, 9, 1792058.	4.6	30
3	Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Science Signaling, 2020, 13, .	3.6	18
4	The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301.	7.0	46
5	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Frontiers in Immunology, 2019, 10, 2766.	4.8	23
6	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 2017, 8, 21539-21553.	1.8	103
7	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	4.6	75
8	Next-generation TCR sequencingÂ-Âa tool to understand T-cell infiltration in human cancers. Journal of Pathology, 2016, 240, 384-386.	4.5	25
9	Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. OncoImmunology, 2016, 5, e1052213.	4.6	51
10	A highâ€throughput <scp>RNA</scp> i screen for detection of immuneâ€checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Molecular Medicine, 2015, 7, 450-463.	6.9	39
11	A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 1061-1071.	4.2	68
12	Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. Immunobiology, 2014, 219, 189-197.	1.9	7
13	On the armament and appearances of human myeloid-derived suppressor cells. Clinical Immunology, 2012, 144, 250-268.	3.2	168
14	Camouflage and sabotage: tumor escape from the immune system. Cancer Immunology, Immunotherapy, 2011, 60, 1161-1171.	4.2	150
15	Immature Immunosuppressive CD14+HLA-DRâ^'/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign. Cancer Research, 2010, 70, 4335-4345.	0.9	366